B
CLB icon

Bailard’s Core Laboratories CLB Stock Holding History

Bailard’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,284
Closed -$1.11M – 433
2017
Q3 		$1.11M Sell
11,284
-4,698
-29% -$455K 0.09% 158
2017
Q2 		$1.62M Sell
15,982
-2,881
-15% -$311K 0.13% 145
2017
Q1 		$2.18M Buy
18,863
+13,892
+279% +$1.61M 0.18% 121
2016
Q4 		$597K Buy
4,971
+310
+7% +$34.3K 0.06% 193
2016
Q3 		$524K Buy
4,661
+1,613
+53% +$186K 0.05% 203
2016
Q2 		$378K Sell
3,048
-587
-16% -$70.9K 0.05% 224
2016
Q1 		$409K Buy
+3,635
New +$378K 0.06% 166
2015
Q4 		– Sell
-2,859
Closed -$285K – 225
2015
Q3 		$285K Buy
2,859
+970
+51% +$105K 0.04% 194
2015
Q2 		$215K Buy
+1,889
New +$229K 0.03% 228

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Bailard's CLB Position: Q4 2017 in Review

Bailard sold out of Core Laboratories (CLB) in Q4 2017, closing a stake of 11,284 shares — an estimated $1.11M sold.

Bailard first reported a position in CLB in Q2 2015 and held it in 9 quarters. The position peaked at $2.18M in Q1 2017. 356 funds tracked by Wall St. Rank hold CLB as of Q4 2017.

  • Bailard reported no remaining Core Laboratories position as of Q4 2017 after selling out during the quarter.
  • Bailard sold 11,284 Core Laboratories shares in Q4 2017, an estimated $1.11M.
  • Bailard first reported a position in Core Laboratories in Q2 2015 and held it in 9 quarters.
  • Bailard's Core Laboratories position peaked at $2.18M in Q1 2017.
  • 356 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2017.

Based on Bailard's 13F filing for Q4 2017, filed 8 Feb 2018.